Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Iovance Biotherapeutics Inc.

www.iovance.com

Latest From Iovance Biotherapeutics Inc.

Opening The Door For Cell Therapy In Solid Tumors

The next frontier for cell therapy is solid tumors – and of the many attempts to move from liquid to solid tumors, tumor infiltrating lymphocytes and other CAR-T constructs are some of the most promising. 

Clinical Trials ImmunoOncology

Keeping Track: Novartis Scores Big Ahead Of US Memorial Day With Approvals For Gene Therapy Zolgensma, Oncologic Piqray

The latest drug development news and highlights from our US FDA Performance Tracker. 
Drug Review Gene Therapy

Five Companies To Watch This ASCO

MacroGenics, Amgen, Celgene, Forty Seven and Iovance are all set to enjoy a good ASCO meeting with promising data for key products revealed in the abstract drop.

Cancer ASCO

Phio Pharma Takes RXi’s Self-Delivering RNAi Technology, Refocuses On Immuno-Oncology

RXi thought it had solved the RNAi delivery issue but was focused on dermatology and ophthalmology. New CEO Dispersyn thought the platform offered more lucrative promise as a way of optimizing IO therapy.

Business Strategies Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Lion Biotechnologies Inc.
  • Genesis Biopharma Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Iovance Biotherapeutics Inc.
  • Senior Management
  • Maria Fardis, PhD, Pres. & CEO
    Timothy Morris, CFO
    Graf Finckenstein, MD, CMO
  • Contact Info
  • Iovance Biotherapeutics Inc.
    Phone: (650) 260-7120
    999 Skyway Rd.
    Ste. 150
    San Carlos, CA 94070
    USA
UsernamePublicRestriction

Register